Omeros completes sale of omidria® franchise to rayner surgical

Seattle--(business wire)--omeros corporation (nasdaq: omer) today announced that it has completed the sale of omidria (phenylephrine and ketorolac intraocular solution) 1.0%/0.3% to rayner surgical group inc., an affiliate of rayner surgical group limited. the transaction was completed pursuant to an asset purchase agreement that was announced on december 2, 2021. omeros received approximately $126 million in cash at closing. in addition, omeros retains and is entitled to collect the full amoun
OMER Ratings Summary
OMER Quant Ranking